Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 13 EP applications Céline Hélène Rouquayrol has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after January 22, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12714163

FORMULATIONS COMPRISING 2 -AMINO- 2- [2- (4 - OCTYLPHENYL) ETHYL]PROPANE -1, 3 - DIOL

IPC classification:
A61K 9/16, A61K 31/137, A61P 37/06
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
PATENT GRANTED
EP12729907

WASH SOLUTION AND METHOD FOR AFFINITY CHROMATOGRAPHY

IPC classification:
C07K 1/22
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP12756466

COMBINATIONS COMPRISING A S1P RECEPTOR MODULATOR

IPC classification:
A61K 31/135, A61K 31/137, A61K 31/343, A61K 31/4525, A61K 45/06, A61P 25/24
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12720757

METHOD OF TREATING VISION DISORDERS

IPC classification:
A61P 27/02, C07K 16/22
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14163450

Solid oral composition comprising a S1P receptor agonist and a sugar alcohol

IPC classification:
A61K 9/20, A61K 9/48, A61K 31/137, A61P 25/00
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP13186359

S1P receptor modulators for treating multiple sclerosis

IPC classification:
A61K 31/137, A61K 31/397, A61P 37/06
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13177175

Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators

IPC classification:
A61K 9/00, A61K 9/20, A61K 9/70, A61K 31/137
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14167553

Combinations comprising MGLUR modulators for the treatment of parkinson's disease

IPC classification:
A61K 31/404, A61K 31/4427, A61K 31/4545, A61K 31/465, A61K 31/4709, A61K 31/4725, A61K 45/06, A61P 25/16
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP14178519

Compound formulations of 2-amino-1,3-propanediol compounds

IPC classification:
A61K 9/00, A61K 31/133, A61K 47/10, A61P 37/00, A61P 37/06
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP13701276

SYRINGE

IPC classification:
A61K 9/00, A61M 5/28, A61M 5/31, A61M 5/315
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13753858

USE OF A VEGF ANTAGONIST IN TREATING OCULAR VASCULAR PROLIFERATIVE DISEASES

IPC classification:
A61K 38/17, A61K 47/48, A61P 27/02
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP15823805

PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES

IPC classification:
A61K 39/395, C07K 16/24
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
Request for examination was made
EP15823803

SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES

IPC classification:
A61K 39/395, C07K 16/24
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
Request for examination was made

Please Sign in to use this feature